CoChat

The Impact of Glucose-Lowering Drugs on Sarcopenia in Type 2 Diabetes: Current Evidence and Underlying Mechanisms

Open access
Massimino, Elena, Izzo, Anna, Riccardi, Gabriele, Della Pepa, Giuseppe · 2021 · Cells
Cited by 102

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

The age-related decrease in skeletal muscle mass together with the loss of muscle power and function is defined sarcopenia. Mounting evidence suggests that the prevalence of sarcopenia is higher in patients with type 2 diabetes mellitus (T2DM), and different mechanisms may be responsible for this association such as impaired insulin sensitivity, chronic hyperglycemia, advanced glycosylation end products, subclinical inflammation, microvascular and macrovascular complications. Glucose-lowering drugs prescribed for patients with T2DM might impact on these mechanisms leading to harmful or beneficial effect on skeletal muscle. Importantly, beyond their glucose-lowering effects, glucose-lowering drugs may affect per se the equilibrium between protein anabolism and catabolism through several mechanisms involved in skeletal muscle physiology, contributing to sarcopenia. The aim of this narrative review is to provide an update on the effects of glucose-lowering drugs on sarcopenia in individuals with T2DM, focusing on the parameters used to define sarcopenia: muscle strength (evaluated by handgrip strength), muscle quantity/quality (evaluated by appendicular lean mass or skeletal muscle mass and their indexes), and physical performance (evaluated by gait speed or short physical performance battery). Furthermore, we also describe the plausible mechanisms by which glucose-lowering drugs may impact on sarcopenia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells10081958

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 104

  1. Filippin, 2015, Sarcopenia: A predictor of mortality and the need for early diagnosis and intervention, Aging Clin. Exp. Res., 27, 249, 10.1007/s40520-014-0281-4 · DOI
  2. Kera, 2019, Defnition of respiratory sarcopenia with peak expiratory fow rate, J. Am. Med. Direct. Assoc., 20, 1021, 10.1016/j.jamda.2018.12.013 · DOI
  3. Nagano, 2021, Respiratory Sarcopenia and Sarcopenic Respiratory Disability: Concepts, Diagnosis, and Treatment, J. Nutr. Health. Aging., 25, 507, 10.1007/s12603-021-1587-5 · DOI · Paper page
  4. Buchman, 2008, Pulmonary function, muscle strength and mortality in old age, Mech. Ageing. Dev., 129, 625, 10.1016/j.mad.2008.07.003 · DOI · Paper page
  5. Okazaki, 2020, Association between sarcopenia and pneumonia in older people, Geriatr. Gerontol. Int., 20, 7, 10.1111/ggi.13839 · DOI · Paper page
  6. Kwak, 2021, Frailty: Past, present, and future?, SMHS, 3, 1
  7. Dennison, 2017, Epidemiology of sarcopenia and insight into possible therapeutic targets, Nat. Rev. Rheumatol., 13, 340, 10.1038/nrrheum.2017.60 · DOI · Paper page
  8. Pourmotabbed, 2020, Sleep duration and sarcopenia risk: A systematic review and dose-response meta-analysis, Sleep Breath, 24, 1267, 10.1007/s11325-019-01965-6 · DOI
  9. Prokopidis, 2021, Effects of sleep deprivation on sarcopenia and obesity: A narrative review of randomized controlled and crossover trials, J. Frailty Sarcopenia Falls, 6, 50, 10.22540/JFSF-06-050 · DOI
  10. Steffl, 2016, Alcohol consumption as a risk factor for sarcopenia—a meta-analysis, BMC Geriatr., 16, 16, 10.1186/s12877-016-0270-x · DOI
  11. Steffl, 2015, Relation between cigarette smoking and sarcopenia: Meta-analysis, Physiol. Res., 64, 419, 10.33549/physiolres.932802 · DOI · Paper page
  12. Lee, 2007, Associated factors and health impact of sarcopenia in older Chinese men and women: A cross-sectional study, Gerontology, 53, 404, 10.1159/000107355 · DOI · Paper page
  13. Tournadre, 2019, Sarcopenia, Jt. Bone Spine, 86, 309, 10.1016/j.jbspin.2018.08.001 · DOI · Paper page
  14. Guillet, 2004, Whole body protein breakdown is less inhibited by insulin, but still responsive to amino acid, in nondiabetic elderly subjects, J. Clin. Endocrinol. Metab., 89, 6017, 10.1210/jc.2003-031323 · DOI · Paper page
  15. Priego, 2018, Hormones and Muscle Atrophy, Adv. Exp. Med. Biol., 1088, 207, 10.1007/978-981-13-1435-3_9 · DOI
  16. Carter, 2019, Lipotoxicity, aging, and muscle contractility: Does fiber type matter?, GeroScience, 41, 297, 10.1007/s11357-019-00077-z · DOI · Paper page
  17. Tuttle, 2020, Markers of inflammation and their association with muscle strength and mass: A systematic review and meta-analysis, Ageing Res. Rev., 64, 101185, 10.1016/j.arr.2020.101185 · DOI · Paper page
  18. McCormick, 2018, Age-related changes in skeletal muscle: Changes to life-style as a therapy, Biogerontology, 19, 519, 10.1007/s10522-018-9775-3 · DOI · Paper page
  19. American Diabetes Association (2020). 12. Older Adults: Standards of Medical Care in Diabetes. Diabetes Care, 43, S152–S162. · DOI · Paper page
  20. Anagnostis, 2020, Type 2 Diabetes Mellitus is Associated with Increased Risk of Sarcopenia: A Systematic Review and Meta-analysis, Calcif Tissue Int., 107, 453, 10.1007/s00223-020-00742-y · DOI · Paper page
  21. Izzo, A., Massimino, E., Riccardi, G., and Della Pepa, G. (2021). A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors. Nutrients, 13. · DOI · Paper page
  22. Veronese, 2019, Effect of nutritional supplementations on physical performance and muscle strength parameters in older people: A systematic review and meta-analysis, Ageing Res. Rev., 51, 48, 10.1016/j.arr.2019.02.005 · DOI · Paper page
  23. Dodds, R.M., Syddall, H.E., Cooper, R., Benzeval, M., Deary, I.J., Dennison, E.M., Der, G., Gale, C.R., Inskip, H.M., and Jagger, C. (2014). Grip strength across the life course: Normative data from twelve British studies. PLoS ONE, 9. · DOI · Paper page
  24. Lee, 2018, Physical Activity and Sarcopenia in the Geriatric Population: A Systematic Review, J. Am. Med. Dir. Assoc., 19, 378, 10.1016/j.jamda.2018.02.003 · DOI · Paper page
  25. Shaw, 2017, Epidemiology of Sarcopenia: Determinants Throughout the Lifecourse, Calcif. Tissue Int., 101, 229, 10.1007/s00223-017-0277-0 · DOI · Paper page
  26. Steffl, 2017, Relationship between sarcopenia and physical activity in older people: A systematic review and meta-analysis, Clin. Interv. Aging, 12, 835, 10.2147/CIA.S132940 · DOI · Paper page
  27. McKendry, J., Currier, B.S., Lim, C., Mcleod, J.C., Thomas, A., and Phillips, S.M. (2020). Nutritional Supplements to Support Resistance Exercise in Countering the Sarcopenia of Aging. Nutrients, 12. · DOI · Paper page
  28. Bloom, I., Shand, C., Cooper, C., Robinson, S., and Baird, J. (2018). Diet Quality and Sarcopenia in Older Adults: A Systematic Review. Nutrients, 10. · DOI · Paper page
  29. Robinson, 2018, ESCEO working group. Does nutrition play a role in the prevention and management of sarcopenia?, Clin. Nutr., 37, 1121, 10.1016/j.clnu.2017.08.016 · DOI · Paper page
  30. Lee, 2020, The Right Diabetes Medication for the Right Patient for the Right Outcome: Can a Network Meta-analysis Help Us Decide?, Ann. Intern. Med., 173, 311, 10.7326/M20-4266 · DOI
  31. Mosenzon, 2021, From glucose lowering agents to disease/diabetes modifying drugs: A "SIMPLE" approach for the treatment of type 2 diabetes, Cardiovasc. Diabetol, 20, 92, 10.1186/s12933-021-01281-y · DOI
  32. Patti, A.M., Rizvi, A.A., Giglio, R.V., Stoian, A.P., Ligi, D., and Mannello, F. (2020). Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes. J. Clin. Med., 9. · DOI · Paper page
  33. Beaudart, 2016, Sarcopenia in daily practice: Assessment and management, BMC Geriatr., 16, 170, 10.1186/s12877-016-0349-4 · DOI · Paper page
  34. Rossi, 2014, Identifying sarcopenia in acute care setting patients, J. Am. Med. Dir. Assoc., 15, e7, 10.1016/j.jamda.2013.11.018 · DOI
  35. Maggio, M., Ceda, G.P., Ticinesi, A., De Vita, F., Gelmini, G., Costantino, C., Meschi, T., Kressig, R.W., Cesari, M., and Fabi, M. (2016). Instrumental and Non-Instrumental Evaluation of 4-Meter Walking Speed in Older Individuals. PLoS ONE, 11. · DOI · Paper page
  36. Podsiadlo, 1991, The timed “Up & Go”: A test of basic functional mobility for frail elderly persons, J. Am. Geriatr. Soc., 39, 142, 10.1111/j.1532-5415.1991.tb01616.x · DOI · Paper page
  37. Bouchi, 2017, Sarcopenia is associated with incident albuminuria in patients with type 2 diabetes: A retrospective observational study, J. Diabetes Investig., 8, 783, 10.1111/jdi.12636 · DOI
  38. Cui, 2020, A cross-sectional study: Associations between sarcopenia and clinical characteristics of patients with type 2 diabetes, Medicine, 99, e18708, 10.1097/MD.0000000000018708 · DOI
  39. Fukuoka, 2019, Importance of physical evaluation using skeletal muscle mass index and body fat percentage to prevent sarcopenia in elderly Japanese diabetes patients, J. Diabetes Investig., 10, 322, 10.1111/jdi.12908 · DOI · Paper page
  40. Yang, 2016, Sarcopenia associated with renal function in the patients with type 2 diabetes, Diabetes Res. Clin. Pract., 118, 121, 10.1016/j.diabres.2016.06.023 · DOI
  41. Aghili, 2014, Body composition in adults with newly diagnosed type 2 diabetes: Effects of metformin, J. Diabetes Metab. Disord., 13, 88, 10.1186/s40200-014-0088-z · DOI · Paper page
  42. Sexton, 2014, Respiratory effects of insulin sensitisation with metformin: A prospective observational study, COPD, 11, 133, 10.3109/15412555.2013.808614 · DOI
  43. Koshizaka, 2021, Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study, Diabetes Ther., 12, 183, 10.1007/s13300-020-00949-0 · DOI
  44. Ishii, 2020, Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Muscle Mass and the Muscle/Fat Ratio in Patients with Type 2 Diabetes, J. Clin. Med. Res., 12, 122, 10.14740/jocmr4078 · DOI
  45. Yajima, 2018, The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis, J. Diabetes Complications, 32, 759, 10.1016/j.jdiacomp.2018.05.018 · DOI · Paper page
  46. Rondanelli, 2016, Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus, Patient Prefer. Adherence, 10, 407
  47. Hong, 2016, Effects of Short-Term Exenatide Treatment on Regional Fat Distribution, Glycated Hemoglobin Levels, and Aortic Pulse Wave Velocity of Obese Type 2 Diabetes Mellitus Patients, Endocrinol. Metab., 31, 80, 10.3803/EnM.2016.31.1.80 · DOI · Paper page
  48. Tsurutani, 2018, Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open-label, active-controlled study, Diabetes Obes. Metab., 20, 2675, 10.1111/dom.13421 · DOI
  49. Sano, 2016, Increased grip strength with sodium-glucose cotransporter 2, J. Diabetes, 8, 736, 10.1111/1753-0407.12402 · DOI
  50. Shimizu, 2019, Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease, Diabetes Obes. Metab., 21, 285, 10.1111/dom.13520 · DOI · Paper page
  51. Sugiyama, 2018, Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes, J. Atheroscler Thromb, 25, 467, 10.5551/jat.40873 · DOI · Paper page
  52. Yamakage, 2020, Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial, J. Diabetes Investig., 11, 653, 10.1111/jdi.13179 · DOI
  53. Tobita, 2017, Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study, Curr. Ther. Res. Clin. Exp., 87, 13, 10.1016/j.curtheres.2017.07.002 · DOI · Paper page
  54. Sasaki, 2019, Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: The Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study, J. Diabetes Investig., 10, 108, 10.1111/jdi.12851 · DOI · Paper page
  55. Bouchi, 2017, Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: A pilot study, Cardiovasc. Diabetol., 16, 32, 10.1186/s12933-017-0516-8 · DOI · Paper page
  56. Inoue, 2019, Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease, J. Diabetes Investig., 10, 1004, 10.1111/jdi.12980 · DOI · Paper page
  57. Inoue, 2019, SUMS-ADDIT-1 Research group. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial, J. Diabetes Investig., 10, 1012, 10.1111/jdi.12985 · DOI
  58. Yamamoto, 2016, Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy, Endocr. J., 63, 589, 10.1507/endocrj.EJ15-0749 · DOI · Paper page
  59. Iemitsu, 2019, Efficacy and Safety of Ipragliflozin in Patients with Type 2 Diabetes: ASSIGN-K Study, J. Endocrinol. Metab., 9, 51, 10.14740/jem570 · DOI
  60. Kato, 2017, Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes receiving conventional therapy: Clinical implication of the importance of exercise habits during treatment with ipragliflozin, Diabetol. Int., 8, 275, 10.1007/s13340-017-0307-1 · DOI
  61. Miyake, 2018, Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease, Open Med., 13, 402, 10.1515/med-2018-0059 · DOI · Paper page
  62. Matsuba, 2018, Tofogliflozin decreases body fat mass and improves peripheral insulin resistance, Diabetes Obes. Metab., 20, 1311, 10.1111/dom.13211 · DOI
  63. Laksmi, 2017, Effect of Metformin on Handgrip Strength, Gait Speed, Myostatin Serum Level, and Health-related Quality of Life: A Double Blind Randomized Controlled Trial among Non-diabetic Pre-frail Elderly Patients, Acta. Med. Indones., 49, 118
  64. Yokota, 2017, Pioglitazone improves whole-body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome, J. Diabetes Investig., 8, 535, 10.1111/jdi.12606 · DOI
  65. Bastien, 2019, Effect of PPARγ agonist on aerobic exercise capacity in relation to body fat distribution in men with type 2 diabetes mellitus and coronary artery disease: A 1-yr randomized study, Am. J. Physiol. Endocrinol. Metab., 317, E65, 10.1152/ajpendo.00505.2018 · DOI
  66. Rizzo, 2016, Sarcopenia in Elderly Diabetic Patients: Role of Dipeptidyl Peptidase 4 Inhibitors, J. Am. Med. Dir. Assoc., 17, 896, 10.1016/j.jamda.2016.04.016 · DOI
  67. Cobo, 2016, Impact of frailty in older patients with diabetes mellitus: An overview, Endocrinol. Nutr., 63, 291, 10.1016/j.endonu.2016.01.004 · DOI
  68. Mesinovic, 2019, Sarcopenia and type 2 diabetes mellitus: A bidirectional relationship, Diabetes Metab. Syndr. Obes., 12, 1057, 10.2147/DMSO.S186600 · DOI · Paper page
  69. Liccini, 2016, Frailty and Sarcopenia as Predictors of Adverse Health Outcomes in Persons with Diabetes Mellitus, J. Am. Med. Dir. Assoc., 17, 846, 10.1016/j.jamda.2016.07.007 · DOI · Paper page
  70. Sazlina, S.G., Lee, P.Y., Chan, Y.M., Hamid, M.S., and Tan, N.C. (2020). The prevalence and factors associated with sarcopenia among community living elderly with type 2 diabetes mellitus in primary care clinics in Malaysia. PLoS ONE, 15. · DOI
  71. Lazarevich, 2020, Sarcopenia, nutritional status and type 2 diabetes mellitus: A cross-sectional study in a group of Mexican women residing in a nursing home, Nutr. Diet., 77, 515, 10.1111/1747-0080.12551 · DOI
  72. Okamura, 2019, Shortage of energy intake rather than protein intake is associated with sarcopenia in elderly patients with type 2 diabetes: A cross-sectional study of the KAMOGAWA-DM cohort, J. Diabetes, 11, 477, 10.1111/1753-0407.12874 · DOI · Paper page
  73. Stangl, 2019, Sarcopenia—Endocrinological and Neurological Aspects, Exp. Clin. Endocrinol. Diabetes, 127, 8
  74. Pereira, 2008, Insulin resistance of protein metabolism in type 2 diabetes, Diabetes, 57, 56, 10.2337/db07-0887 · DOI · Paper page
  75. Das, 2012, AMP-activated protein kinase stimulates myostatin expression in C2C12 cells, Biochem. Biophys. Res. Commun., 427, 36, 10.1016/j.bbrc.2012.08.138 · DOI
  76. Kalyani, 2013, Quadriceps strength, quadriceps power, and gait speed in older U.S. adults with diabetes mellitus: Results from the National Health and Nutrition Examination Survey, 1999-2002, J. Am. Geriat.r Soc., 61, 769, 10.1111/jgs.12204 · DOI · Paper page
  77. Oberbach, 2006, Altered fiber distribution and fiber-specific glycolytic and oxidative enzyme activity in skeletal muscle of patients with type 2 diabetes, Diabetes Care, 29, 895, 10.2337/diacare.29.04.06.dc05-1854 · DOI · Paper page
  78. Nezameddin, 2020, Understanding Sarcopenic Obesity in Terms of Definition and Health Consequences: A Clinical Review, Curr. Diabetes Rev., 16, 957, 10.2174/1573399816666200109091449 · DOI · Paper page
  79. Haus, 2007, Collagen, cross-linking, and advanced glycation end products in aging human skeletal muscle, J. Appl. Physiol., 103, 2068, 10.1152/japplphysiol.00670.2007 · DOI · Paper page
  80. Mori, 2019, Association of accumulated advanced glycation end-products with a high prevalence of sarcopenia and dynapenia in patients with type 2 diabetes, J. Diabetes Investig., 10, 1332, 10.1111/jdi.13014 · DOI · Paper page
  81. Ighodaro, 2018, Molecular pathways associated with oxidative stress in diabetes mellitus, Biomed. Pharmacother., 108, 656, 10.1016/j.biopha.2018.09.058 · DOI · Paper page
  82. Yaribeygi, 2020, Molecular Mechanisms Linking Oxidative Stress and Diabetes Mellitus, Oxid. Med. Cell. Longev., 2020, 8609213, 10.1155/2020/8609213 · DOI · Paper page
  83. Zhang, 2020, Oxidative stress and diabetes: Antioxidative strategies, Front Med., 14, 583, 10.1007/s11684-019-0729-1 · DOI · Paper page
  84. Bellanti, F., Lo Buglio, A., and Vendemiale, G. (2020). Chapter 9-Oxidative stress and sarcopenia. Aging, 95–103. · DOI
  85. Gupta, 2017, Association Between the Severity of Diabetic Retinopathy and Falls in an Asian Population with Diabetes: The Singapore Epidemiology of Eye Diseases Study, JAMA Ophthalmol., 135, 1410, 10.1001/jamaophthalmol.2017.4983 · DOI
  86. Fukuda, 2017, Association of diabetic retinopathy with both sarcopenia and muscle quality in patients with type 2 diabetes: A cross-sectional study, BMJ Open Diabetes Res. Care, 5, 1, 10.1136/bmjdrc-2017-000404 · DOI
  87. Wang, 2014, Mechanisms of muscle wasting in chronic kidney disease, Nat. Rev. Nephrol., 10, 504, 10.1038/nrneph.2014.112 · DOI · Paper page
  88. Nomura, 2018, Diabetic polyneuropathy is a risk factor for decline of lower extremity strength in patients with type 2 diabetes, J. Diabetes Investig., 9, 186, 10.1111/jdi.12658 · DOI
  89. Parasoglou, 2017, Declining Skeletal Muscle Function in Diabetic Peripheral Neuropathy, Clin. Ther., 6, 1085, 10.1016/j.clinthera.2017.05.001 · DOI
  90. Dziubek, 2015, Peripheral arterial disease decreases muscle torque and functional walking capacity in elderly, Maturitas, 81, 480, 10.1016/j.maturitas.2015.06.001 · doi:10.1016/j.maturitas.2015.06.001
  91. LaMoia, 2021, Cellular and Molecular Mechanisms of Metformin Action, Endocr Rev, 42, 77, 10.1210/endrev/bnaa023 · DOI · Paper page
  92. Kristensen, 2014, Two weeks of metformin treatment induces AMPK-dependent enhancement of insulin-stimulated glucose uptake in mouse soleus muscle, Am. J. Physiol. Endocrinol. Metab., 306, E1099, 10.1152/ajpendo.00417.2013 · DOI
  93. Kwon, 2015, Palmitate activates mTOR/p70S6K through AMPK inhibition and hypophosphorylation of raptor in skeletal muscle cells: Reversal by oleate is similar to metformin, Biochimie, 118, 141, 10.1016/j.biochi.2015.09.006 · DOI
  94. Boushel, 2010, Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes, Diabetes Obes. Metab., 12, 806, 10.1111/j.1463-1326.2010.01237.x · DOI · Paper page
  95. Coletta, 2009, Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: A randomised trial, Diabetologia, 52, 723, 10.1007/s00125-008-1256-9 · DOI · Paper page
  96. Zeng, 2020, Pharmacogenomic Studies of Current Antidiabetic Agents and Potential New Drug Targets for Precision Medicine of Diabetes, Diabetes Ther., 11, 2521, 10.1007/s13300-020-00922-x · DOI
  97. Gilbert, 2020, GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head, Front Endocrinol., 11, 178, 10.3389/fendo.2020.00178 · DOI · Paper page
  98. Rizzo, 2012, Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: Role of dipeptidyl peptidase-IV inhibition, Diabetes Care, 35, 2076, 10.2337/dc12-0199 · DOI · Paper page
  99. Holst, 2014, GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle, Am. J. Physiol. Endocrinol. Metab., 306, E355, 10.1152/ajpendo.00283.2013 · DOI · Paper page
  100. Yamamoto, K., Amako, M., Yamamoto, Y., Tsuchihara, T., Nukada, H., Yoshihara, Y., Arino, H., Fujita, M., Uenoyama, M., and Tachibana, S. (2013). Therapeutic effect of exendin-4, a long-acting analogue of glucagon-like peptide-1 receptor agonist, on nerve regeneration after the crush nerve injury. Biomed. Res. Int., 315848. · DOI
  101. Sasaki, 2019, Sarcopenia, frailty circle and treatment with sodium-glucose cotransporter 2 inhibitors, J. Diabetes Investig., 10, 193, 10.1111/jdi.12966 · DOI · Paper page
  102. Bonnet, 2018, Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease, Diabetes Metab., 44, 457, 10.1016/j.diabet.2018.09.005 · DOI · Paper page
  103. Esterline, 2018, Mechanisms in endocrinology: SGLT2 inhibitors: Clinical benefits by restoration of normal diurnal metabolism?, Eur. J. Endocrinol., 178, R113, 10.1530/EJE-17-0832 · DOI · Paper page
  104. Murphy, 2018, Nutrition and physical activity countermeasures for sarcopenia: Time to get personal?, Nutr. Bull., 43, 374, 10.1111/nbu.12351 · DOI

Cited by

See all 102

Metadata

Authors
Massimino, E., Izzo, A., Riccardi, G., & Della Pepa, G.
Venue
Cells
Publisher
MDPI AG
Published
2021-08-01
Volume
10
Issue
8
Pages
1958
ISSN
2073-4409 (ISSN-L)
OpenAlex
W3192186764
Cited by
102
References
50
FWCI
7.44
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.